Amlesh R
Friday, March 13, 2026
26.2
C
Bengaluru
Hot topics
Biocon Bats for Affordable Insulin and Ozempic
🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
You can Lead People
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, Soham Wagh and Amit Jain
Raja Reddy – 7 Thinking Patterns that Shaped My Career
Raja Reddy is presently the head of marketing at Servier...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
Hot topics
The Pharma Professional’s Guide
Brand Building Special Issue with articles on personal branding, brand differentiation and avoiding brand arrogance
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Pfizer’s $4.9 Billion Bet: A Game-Changing Move in Obesity Therapeutics
Pfizer’s acquisition of Metsera, announced on September 22, 2025,...
The Rise and Fall of A.H. Robins Company: A Tale of Innovation Marred by One Acquisition
A.H. Robins Company was a formidable name in the...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Newsletter
Get important news delivered directly to your inbox and stay connected!